Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 3:18:277-289.
doi: 10.2147/DDDT.S426947. eCollection 2024.

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Michael J Cork  1   2 , Simon G Danby  1   2 , Ana B Rossi  3 , Ashish Bansal  4
Affiliations
Review

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Michael J Cork et al. Drug Des Devel Ther. .

Abstract

Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Children with severe AD have a multidimensional disease burden characterized by skin lesions, itching, frequent infections, sleep deprivation, and a high rate of comorbidities. These impact the mental health and overall quality of life of not only the children but also of their parents and caregivers. There are few effective available treatment options for young children with severe AD that are suitable for long-term use. Due to their adverse effects, practice guidelines consider systemic agents inappropriate for this age group, although they are still used off-label in extreme cases. The biologic dupilumab has recently been approved for children aged 6-11 years with severe (EU) and moderate-to-severe (USA) AD, offering hope to this population of patients with a high unmet clinical need. The purpose of this review is to describe the unmet needs of AD patients aged 6-11 years prior to dupilumab approval and to summarize existing clinical data supporting dupilumab's safety and efficacy in these children.

Keywords: atopic dermatitis; children; dupilumab; pediatric; severe.

PubMed Disclaimer

Conflict of interest statement

Professor Michael J Cork has served as a consultant and/or advisory board member and/or received research grants from Almirall, Amgen, Astellas Pharma, Bayer, GSK, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L’Oréal, Novartis, Perrigo, Pfizer, Procter & Gamble, Sanofi, Stiefel, Regeneron Pharmaceuticals Inc., and Unilever. Professor Michael J Cork is a voluntary medical advisor to the National Eczema Society UK. Dr Simon G Danby reports grants from Sanofi, Almirall, Johnson & Johnson, and Leo Pharma; grants, personal fees from Perrigo, Pfizer, and Hyphens Pharma, outside the submitted work. Dr Ana B. Rossi is an employee of and may hold stock and/or stock options in Sanofi. Dr Ashish Bansal is an employee and shareholder of Regeneron Pharmaceuticals Inc.

Figures

Figure 1
Figure 1
Clinical signs of atopic dermatitis in infants (A) and children (B). Photos courtesy of Dr Tanigushi Abagge. Caregivers and investigators authorized the publication of these photos.
Figure 2
Figure 2
Dupilumab pediatric development program: clinical trials.
Figure 3
Figure 3
Images of dupilumab efficacy before and after treatment. (A) Photo of a patient with AD signs and symptoms depicted in rainbow graphics (B) and spider plots (C) before and after dupilumab treatment in AD-1652. The rainbow graphics show changes in scores from baseline to Week 16. The spider plots show percent improvement from baseline to Week 16. Caregivers and investigators authorized the publication of these photos.
Figure 4
Figure 4
Rate of infections and skin infections in LIBERTY AD PEDS (NCT03345914).
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi:10.1016/j.anai.2020.12.020 - DOI - PubMed
    1. Paller AS, Guttman-Yassky E, Schuttelaar ML, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD real-world registry. J Am Acad Dermatol. 2022;87(5):1104–1108. doi:10.1016/j.jaad.2022.01.018 - DOI - PubMed
    1. Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220–226.e5. doi:10.1016/j.jpeds.2022.04.027 - DOI - PubMed
    1. Silverberg JI, Simpson EL, Weidinger S, et al. Children with atopic dermatitis (AD) have a high burden of atopic comorbidities: results from a large worldwide survey. J Allergy Clin Immunol. 2021;147(2):AB31. doi:10.1016/j.jaci.2020.12.149 - DOI
    1. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi:10.1016/j.jaad.2014.03.030 - DOI - PMC - PubMed

Substances